… Belani CP, Natale RB, Lee JS, et al: Randomized phase III trial comparing cisplatin/etoposide
versus carboplatin/paclitaxel in advanced and metastatic non-small cell lung cancer (…

… -blind, randomized phase III study tested the safety and efficacy of darbepoetin alfa
administered weekly for the treatment of anemia in patients with lung cancer receiving multicycle …

… patients and the only agent for which phase III data exists in a large number of patients
with prior platinum therapy. In the first of two randomized phase III trials, median survival with …

… The impact of BV on survival would be best assessed in a larger randomized phase III
setting. A randomized, open-label, parallel assignment phase II to III trial in Europe (IFCT […

… In a randomized phase III trial, 610 patients with inoperable stage II or III non–small cell
lung cancer were randomly assigned to two different concurrent regimens (chemotherapy with …

… -label, randomized trial to evaluate the addition of a primary prophylactic dose of LMWH
for 24 weeks to standard treatment in patients with newly diagnosed lung cancer of any stage …

… , lung cancer continues to be the leading cause of cancer deaths in … cancer combined.
Radical surgery remains the cornerstone of treatment for early-stage non–small-cell lung cancer (…

Purpose To evaluate the effect of BLP25 liposome vaccine (L-BLP25) on survival and
toxicity in patients with stage IIIB and IV non–small-cell lung cancer (NSCLC). Secondary …

… Lung cancer is the most common cancer in the world today (12.3% of all new cases), with …
deaths (17.8% of all cancer deaths) worldwide in 2000. Non—small-cell lung cancer (NSCLC) …

Purpose We conducted a phase III study to compare the survival impact of concurrent versus
sequential treatment with radiotherapy (RT) and chemotherapy (CT) in unresectable stage …